Autolus Therapeutics (6A3A) Price & Analysis

3 Followers

6A3A Stock Chart & Stats

€1.32

€0.08(6.45%)

At close: Jul 24 4:00 PM EDT

€1.32

€0.08(6.45%)

Day’s Range― - ―

52-Week Range€1.04 - €2.16

Previous CloseN/A

Volume0.00

Average Volume (3M)1.20K

Market Cap

€557.08M

Enterprise Value€590.54

Total Cash (Recent Filing)€201.63M

Total Debt (Recent Filing)€83.51M

Price to Earnings (P/E)―

Beta1.32

Next Earnings

Oct 29, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.06

Shares Outstanding266,162,540

10 Day Avg. Volume0

30 Day Avg. Volume1,203

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)2.97

Price to Sales (P/S)7.01

P/FCF Ratio-1.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€7.05

Price Target Upside433.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.69

Revenue Forecast (FY)€126.66M

Bulls Say, Bears Say

Bulls Say

Accelerating AUCATZYL Commercial GrowthRapid product revenue growth and the higher full-year outlook indicate strengthening adoption of AUCATZYL. Sustained commercial traction could improve operating leverage and gradually shift Autolus toward a more durable product-led revenue model.

Improving Gross Margins And Manufacturing EconomicsThe margin inflection, supported by higher volumes and Nucleus facility production, suggests manufacturing efficiency is improving. Reaching the targeted mature margin range would strengthen contribution economics and reduce the funding burden of commercialization.

Broader Treatment-center Reach And Pipeline OptionalityA larger treatment-center network expands patient access and supports repeatable commercial execution. Meanwhile, programs such as AUTO8, BOBCAT, CATULUS and LUMINA provide longer-term product and indication optionality beyond the current lead therapy.

Bears Say

Persistent Losses And Substantial Cash BurnAutolus remains dependent on external funding while operating cash outflows are substantial. Unless revenue growth and gross-margin gains translate into stronger operating leverage, continued losses could consume liquidity and create recurring financing needs.

Financing Depends On Milestones And Adds Financial ObligationsMilestone-linked financing makes part of the expected liquidity runway dependent on execution against revenue targets. Secured obligations, floating interest costs and potential warrant issuance may constrain flexibility and increase shareholder dilution risk.

High Commercialization And Development Cost BaseAutolus is investing heavily in commercial infrastructure and its clinical pipeline while still operating at a loss. These costs may support future growth, but they also delay breakeven and raise execution risk if adoption or trial outcomes fall short.

Autolus Therapeutics News

Autolus Therapeutics raises FY26 revenue view to $140M-$150M from $120M-$135M

Coonsensus $139.42M. The company said, “Autolus recently increased the full year 2026 guidance for AUCATZYL net product revenue...

16d ago

AUTL

Autolus Therapeutics reports Q2 EPS (15c), consensus (19c)

Reports Q2 revenue $45.69M, consensus $40.15M. “In the second quarter we achieved substantial sales growth in the ongoing...

16d ago

AUTL

Autolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M

“In the second quarter, AUCATZYL sales increased approximately 70% over Q1 2026 and more than 100% compared to...

24d ago

AUTL

Autolus Therapeutics Earnings Call Highlights Growth Momentum

Autolus Therapeutics (($AUTL)) has held its Q2 earnings call. Read on for the main highlights of the call....

5d ago

AUTL

Gil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory

Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics and keeping the price target at...

16d ago

AUTL

Autolus Lifts 2026 Guidance as AUCATZYL Sales Surge

Autolus Therapeutics ( ($AUTL) ) has shared an update. In the quarter ended June 30, 2026, Autolus Therapeutics...

16d ago

AUTL

AUTL Upcoming Earnings Report: What to Expect?

Autolus Therapeutics (AUTL) is scheduled to report 2nd quarter earnings on 08/11/2026, before the market opens. Regarding Q2...

18d ago

AUTL

Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Outperforms and Non-Dilutive Financing Extends Runway; $10 Price Target Maintained

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Autolus Therapeutics. The associated price target...

24d ago

AUTL

Autolus Raises AUCATZYL Outlook, Secures New Credit Facility

Autolus Therapeutics ( ($AUTL) ) has issued an announcement. Autolus Therapeutics raised its full-year 2026 guidance for AUCATZYL...

24d ago

AUTL

Autolus Secures New $250 Million Financing and Warrants

Autolus Therapeutics ( ($AUTL) ) has provided an announcement. Autolus Therapeutics entered into a senior secured notes facility...

24d ago

AUTL

Autolus shareholders approve 2025 accounts and board slate

Autolus Therapeutics ( ($AUTL) ) just unveiled an announcement. On June 29, 2026, Autolus Therapeutics held its 2026...

2M ago

AUTL

Autolus Schedules 2026 AGM and Engages ADS Holders

Autolus Therapeutics ( ($AUTL) ) has shared an update. On June 5, 2026, Autolus Therapeutics published its UK...

3M ago

AUTL

Autolus Therapeutics Signals Turning Point in Earnings

Autolus Therapeutics (($AUTL)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

AUTL

Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $9 and keeps a...

3M ago

AUTL

6A3A FAQ

What was Autolus Therapeutics’s price range in the past 12 months?

Autolus Therapeutics lowest stock price was €1.04 and its highest was €2.16 in the past 12 months.

What is Autolus Therapeutics’s market cap?

Autolus Therapeutics’s market cap is €557.08M.

When is Autolus Therapeutics’s upcoming earnings report date?

Autolus Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 63 days.

How were Autolus Therapeutics’s earnings last quarter?

Autolus Therapeutics released its earnings results on Aug 11, 2026. The company reported -€0.129 earnings per share for the quarter, beating the consensus estimate of -€0.167 by €0.038.

Is Autolus Therapeutics overvalued?

According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Autolus Therapeutics pay dividends?

Autolus Therapeutics does not currently pay dividends.

What is Autolus Therapeutics’s EPS estimate?

Autolus Therapeutics’s EPS estimate is -0.14.

How many shares outstanding does Autolus Therapeutics have?

Autolus Therapeutics has 266,162,540 shares outstanding.

What happened to Autolus Therapeutics’s price movement after its last earnings report?

Autolus Therapeutics reported an EPS of -€0.129 in its last earnings report, beating expectations of -€0.167. Following the earnings report the stock price went up 7.821%.

Which hedge fund is a major shareholder of Autolus Therapeutics?

Currently, no hedge funds are holding shares in DE:6A3A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Autolus Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-31.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Autolus Therapeutics

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Autolus Therapeutics (6A3A) Earnings & Revenues

Historic Earnings Reports

6A3A Company Deck

6A3A Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.View all DE:6A3A earnings summaries

6A3A Stock 12 Month Forecast

Average Price Target

€7.05

▲(433.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.6377044,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.0483667904,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.3188522,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.319,1.8819772615384616,2.444954523076923,3.007931784615385,3.5709090461538464,4.133886307692308,4.69686356923077,5.259840830769232,5.822818092307693,6.385795353846155,6.948772615384616,7.511749876923077,8.07472713846154,{"y":8.6377044,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.319,1.7597205223384615,2.200441044676923,2.6411615670153843,3.0818820893538463,3.5226026116923075,3.963323134030769,4.404043656369231,4.844764178707692,5.285484701046154,5.726205223384615,6.166925745723077,6.607646268061538,{"y":7.0483667904,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.319,1.5497578615384615,1.780515723076923,2.0112735846153846,2.242031446153846,2.4727893076923078,2.7035471692307693,2.934305030769231,3.1650628923076924,3.395820753846154,3.6265786153846156,3.857336476923077,4.088094338461539,{"y":4.3188522,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.589,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.319,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >